Strategies for maintaining results Three approaches can help preserve the benefits achieved during retatrutide treatment
For example, in a study, participants on semaglutide lost, on average, 14.9% of their body weight compared to 2.4% with placebo
By end user, the homecare settings segment dominated the market with a share of 64% in 2025 and is expected to grow at the fastest CAGR of 15.1% in the coming years
For managing pernicious anaemia at this time, there are several options: Stopping B12 treatment is dangerous for patients For people with B12 deficiency , whether due to Pernicious Anaemia or any other caue, doing without their regular treatment is simply not an option
This timeline reveals important patterns
Post-treatment weight regain following discontinuation of GLP-1 receptor agonist therapy